论文部分内容阅读
目的:女性心房颤动(AF)患者脑卒中的风险高于男性。华法林可预防脑卒中,但是由治疗引起的出血在女性中比男性中更多见。方法与结果:SPORTIF III试验(公开标记,n=3410)和SPORTIF V试验(双盲,n=3922)共纳入2257例伴有至少一个脑卒中危险因素的女性AF患者,受试者被随机分配到华法林治疗组[目标国际标准化比值(INR)2.0～3.0]或希美加群组(36m g,2次/d)。主要终点事件为所有脑卒中(包括缺血性和出血性)和全身性栓塞事件。女性患者的平均年龄较男性大(73.4±8.0岁vs69.8±9.0岁,P<0.0001)。
PURPOSE: The risk of stroke in female patients with atrial fibrillation (AF) is higher than that of men. Warfarin prevents stroke, but bleeding caused by treatment is more common in women than in men. METHODS AND RESULTS: A total of 2257 female AF patients with at least one risk factor for stroke were enrolled in the SPORTIF III trial (open label, n = 3410) and the SPORTIF V trial (double blind, n = 3922). Subjects were randomized To warfarin treatment group [target international normalized ratio (INR) 2.0 ~ 3.0] or the Xi Mei Jia group (36m g, 2 times / d). The primary endpoint was all stroke (including ischemic and hemorrhagic) and systemic embolic events. The average age of females was larger than males (73.4 ± 8.0 vs 69.8 ± 9.0 years, P <0.0001).